Liver Cancer

>

Latest News

Investigators are assessing the safety, tolerability, and initial efficacy of BST02 in those with advanced or metastatic liver cancer as part of a phase 1 trial.
BST02 Receives FDA Fast Track Designation in Liver Cancer Management

February 5th 2024

Investigators are assessing the safety, tolerability, and initial efficacy of BST02 in those with advanced or metastatic liver cancer as part of a phase 1 trial.

At 1 and 2 years, patients with hepatocellular carcinoma and narrow surgical margins experienced encouraging recurrence-free survival rates following adjuvant radiotherapy in the phase 2 RAISE trial.
Postoperative IMRT Improves RFS in Hepatocellular Carcinoma

January 30th 2024

Duration of response results with pembrolizumab plus lenvatinib in advanced hepatocellular carcinoma appear to be ‘promising’ in the phase 3 LEAP-002 trial.
Pembrolizumab Combo Improves PFS/OS in Hepatocellular Carcinoma

January 21st 2024

Durvalumab plus bevacizumab and TACE may be a new standard of care in unresectable hepatocellular carcinoma eligible for embolization, according to Riccardo Lencioni, MD.
Durvalumab Combo Improves PFS in Unresectable Hepatocellular Carcinoma

January 20th 2024

Patients with hepatocellular carcinoma and Child-Pugh-B liver function appear to have worse overall survival following treatment with regorafenib in the REFINE trial.
Poor Liver Function HCC Population More Likely to Discontinue Regorafenib

January 20th 2024

Video Interviews
Podcasts
Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.

More News